SEC Form 4 · accession 0001651844-16-000021

NYMOX PHARMACEUTICAL CORP · NYMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 5, 2016

Accepted (ET)

Jul 7, 2016 · 6:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001018735

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 5, 2016	P	2,500	$3.43	A	2,850,050	D
Common Stock	Jul 5, 2016	P	2,500	$3.41	A	2,852,550	D
Common Stock	Jul 6, 2016	P	2,500	$3.33	A	2,855,050	D
Common Stock	Jul 6, 2016	P	2,500	$3.33	A	2,857,550	D
Common Stock	Jul 6, 2016	P	2,500	$3.20	A	2,860,050	D
Common Stock	Jul 6, 2016	P	911	$3.21	A	2,860,961	D
Common Stock	Jul 7, 2016	P	4,089	$3.17	A	2,865,050	D
Common Stock	Jul 7, 2016	P	2,500	$3.20	A	2,867,550	D
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust

No Table II lines on this filing.